HighTower Advisors
MBRX icon

HighTower Advisors’s Moleculin Biotech MBRX Stock Holding History

HighTower Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12
Closed -$21K – 3180
2020
Q4 		$21K Buy
+12
New +$21.3K ﹤0.01% 2477

Other funds holding MBRX

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

HighTower Advisors's MBRX Position: Q1 2021 in Review

HighTower Advisors sold out of Moleculin Biotech (MBRX) in Q1 2021, closing a stake of 12 shares — an estimated $21K sold.

HighTower Advisors first reported a position in MBRX in Q4 2020 and held it in 1 quarter. The position peaked at $21K in Q4 2020. 27 funds tracked by Wall St. Rank hold MBRX as of Q1 2021.

  • HighTower Advisors reported no remaining Moleculin Biotech position as of Q1 2021 after selling out during the quarter.
  • HighTower Advisors sold 12 Moleculin Biotech shares in Q1 2021, an estimated $21K.
  • HighTower Advisors first reported a position in Moleculin Biotech in Q4 2020 and held it in 1 quarter.
  • HighTower Advisors's Moleculin Biotech position peaked at $21K in Q4 2020.
  • 27 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2021.

Based on HighTower Advisors's 13F filing for Q1 2021, filed 10 May 2021.